Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. RXST
6. SPGI
7. RIVN
8. LMT
9. AGIO
10. BFH

Go back to Minerva Neurosciences (NERV) Phase 3 Trial of Roluperidone for Treatment of Negative Symptoms in Schizophrenia Did Not Meet Its Primary and Key Secondary Endpoints

Minerva Neurosciences (NERV) to Resume Trading at 9:50 am

May 29, 2020 9:26 AM EDT

Minerva Neurosciences (NASDAQ: NERV) to Resume Trading at 9:50 am

... More